Media coverage about Neurocrine Biosciences (NASDAQ:NBIX) has trended somewhat positive recently, according to Accern. The research group scores the sentiment of press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Neurocrine Biosciences earned a coverage optimism score of 0.17 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 47.1762259889147 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
These are some of the media headlines that may have impacted Accern’s scoring:
- AbbVie Announces Positive Topline Results from Second Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids (prnewswire.com)
- Zacks: Analysts Expect Neurocrine Biosciences, Inc. (NBIX) to Announce -$0.32 Earnings Per Share (americanbankingnews.com)
- Top Penny Stocks to Watch This Week (March 12) (moneymorning.com)
- Insider Selling: Neurocrine Biosciences, Inc. (NBIX) Insider Sells 75,873 Shares of Stock (americanbankingnews.com)
- Neurocrine Biosciences to Present at Upcoming Healthcare Conferences (finance.yahoo.com)
Several equities analysts have recently weighed in on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $110.00 target price (up from $95.00) on shares of Neurocrine Biosciences in a report on Thursday, February 22nd. BidaskClub raised shares of Neurocrine Biosciences from a “hold” rating to a “buy” rating in a research note on Thursday, January 4th. Deutsche Bank lifted their price target on shares of Neurocrine Biosciences to $97.00 and gave the company a “buy” rating in a research note on Wednesday, February 14th. Oppenheimer set a $110.00 price target on shares of Neurocrine Biosciences and gave the company a “buy” rating in a research note on Thursday, February 22nd. Finally, JPMorgan Chase & Co. lifted their price target on shares of Neurocrine Biosciences from $79.00 to $100.00 and gave the company an “overweight” rating in a research note on Wednesday, February 14th. One equities research analyst has rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. Neurocrine Biosciences currently has an average rating of “Buy” and an average target price of $92.38.
Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings results on Tuesday, February 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.11). The company had revenue of $94.52 million for the quarter, compared to analysts’ expectations of $94.00 million. During the same quarter in the prior year, the company earned ($0.51) earnings per share. sell-side analysts predict that Neurocrine Biosciences will post -0.25 EPS for the current fiscal year.
In other Neurocrine Biosciences news, insider Darin Lippoldt sold 15,237 shares of Neurocrine Biosciences stock in a transaction on Thursday, December 28th. The shares were sold at an average price of $75.00, for a total transaction of $1,142,775.00. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Kevin Charles Gorman sold 3,750 shares of Neurocrine Biosciences stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $78.89, for a total transaction of $295,837.50. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 399,589 shares of company stock worth $32,443,795. 4.80% of the stock is currently owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: This story was reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this story on another site, it was stolen and reposted in violation of US & international copyright legislation. The original version of this story can be read at https://www.tickerreport.com/banking-finance/3260357/neurocrine-biosciences-nbix-getting-somewhat-favorable-press-coverage-study-finds.html.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.